Interpretive Summaries, March 2021

Evaluation of Complications of Covid-19 in Children Admitted to Shahid Sadoughi Hospital in Yazd (March 2020 - March 2021)

Introduction: The World Health Organization first reported outbreaks of COVID-19 in 2019 in Wuhan, China. Limited studies have been performed on long-term complications after the acute phase of this disease in children. This study aimed to evaluate the long-term outcomes of children who had previously been hospitalized with COVID-19. Methods: In this cross-sectional study, long-term complicat...

Summaries of safety labeling changes approved by FDA-boxed warnings highlights March-June 2016.

Class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), includes Anaprox (naproxen), Ansaid (flurbiprofen), Arthrotec (diclofenac sodium/misoprostil), Caldolor (ibuprofen), Cambia (diclofenac potassium), Cataflam (diclofenac), Celebrex (celecoxib), Daypro (oxaprozin), Daypro Alta (oxaprozin), Duexis (ibuprofen and famotidine), Dyloject (diclofenac), Feldene (piroxicam), Flector (diclofenac), In...

Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2017.

As part of FDA’s MedWatch program, important changes to the safety labeling of drugs and therapeutic biologics, including boxed warnings, are posted on the agency’s website. Boxed warnings are ordinarily used to highlight (1) an adverse reaction so serious in proportion to the potential benefit from the drug that it is essential that the reaction be considered in assessing the risks and benefit...

EMBL Programme 2017-2021: Digital Biology

Summaries ∗

Current techniques for validating and verifying program changes often consider the entire program, even for small changes, leading to enormous V&V costs over a program’s lifetime. This is due, in large part, to the use of syntactic program differencing techniques which are necessarily imprecise. Building on recent advances in symbolic execution of heap manipulating programs, in this paper, we d...